Skip to main content

Main menu

  • Home
  • Content
    • Current issue
    • Past issues
    • Early releases
    • Collections
    • Sections
    • Blog
    • Infographics & illustrations
    • Podcasts
    • COVID-19 articles
    • Obituary notices
  • Authors & Reviewers
    • Overview for authors
    • Submission guidelines
    • Submit a manuscript
    • Forms
    • Editorial process
    • Editorial policies
    • Peer review process
    • Publication fees
    • Reprint requests
    • Open access
    • Patient engagement
  • Physicians & Subscribers
    • Benefits for Canadian physicians
    • CPD Credits for CMA Members
    • Subscribe to CMAJ Print
    • Subscription prices
    • Obituary notices
  • Alerts
    • Email alerts
    • RSS
  • JAMC
    • À propos
    • Numéro en cours
    • Archives
    • Sections
    • Abonnement
    • Alertes
    • Trousse média 2023
    • Avis de décès
  • CMAJ JOURNALS
    • CMAJ Open
    • CJS
    • JAMC
    • JPN

User menu

Search

  • Advanced search
CMAJ
  • CMAJ JOURNALS
    • CMAJ Open
    • CJS
    • JAMC
    • JPN
CMAJ

Advanced Search

  • Home
  • Content
    • Current issue
    • Past issues
    • Early releases
    • Collections
    • Sections
    • Blog
    • Infographics & illustrations
    • Podcasts
    • COVID-19 articles
    • Obituary notices
  • Authors & Reviewers
    • Overview for authors
    • Submission guidelines
    • Submit a manuscript
    • Forms
    • Editorial process
    • Editorial policies
    • Peer review process
    • Publication fees
    • Reprint requests
    • Open access
    • Patient engagement
  • Physicians & Subscribers
    • Benefits for Canadian physicians
    • CPD Credits for CMA Members
    • Subscribe to CMAJ Print
    • Subscription prices
    • Obituary notices
  • Alerts
    • Email alerts
    • RSS
  • JAMC
    • À propos
    • Numéro en cours
    • Archives
    • Sections
    • Abonnement
    • Alertes
    • Trousse média 2023
    • Avis de décès
  • Visit CMAJ on Facebook
  • Follow CMAJ on Twitter
  • Follow CMAJ on Instagram
  • Listen to CMAJ podcasts
Commentary

Generic isotretinoin: a new risk for unborn children

Gideon Koren, Marina Avner and Neil Shear
CMAJ May 11, 2004 170 (10) 1567-1568; DOI: https://doi.org/10.1503/cmaj.1040317
Gideon Koren
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Marina Avner
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Neil Shear
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Tables
  • Responses
  • Metrics
  • PDF
Loading
  • © 2004 Canadian Medical Association or its licensors

The introduction of isotretinoin (Accutane) in 1982 was a milestone in the treatment of recalcitrant nodular acne. Although the severe teratogenic effects of the drug quickly became evident,1 its use rapidly increased and was inappropriately extended to patients with less severe forms of acne.2,3 Of 1000 patients who participated in an international survey in 1997, 45% did not have the labelled indication for the drug.4 Also, new off-label uses have emerged, including treatment of dermatologic conditions such as gram-negative folliculitis, recalcitrant rosacea, pyoderma faciale, generalized lichen planus, psoriasis, cutaneous lupus erythematosus and acne fulminans5 —as well as, more recently, the treatment of squamous cell carcinomas6and leukemias.7

Pre-market studies in animals showed high rates of central nervous system and facial malformation after gestational exposure; indeed, within months of the introduction of isotretinoin into the market, severe malformations reported in infants of women taking the drug revealed that it is a potent human teratogen.8 Box 1 presents the features of isotretinoin embryopathy. About 40% of infants exposed to isotretinoin in the first trimester will have major malformations. In addition, children exposed in utero who are spared from major malformation may still be affected by cognitive deficits.

Figure
  • Download figure
  • Open in new tab
  • Download powerpoint

Box 1.

In 1988 the US Food and Drug Administration (FDA) and the manufacturer of Accutane (Roche) developed a Pregnancy Prevention Program aimed at increasing women's awareness of the teratogenicity of the drug and of the importance of preventing conception.9 This program called for women to give written informed consent and commit to using 2 contraceptive methods simultaneously while taking isotretinoin therapy (see Box 2). This program was adopted by Health Canada soon after.

Figure
  • Download figure
  • Open in new tab
  • Download powerpoint

Box 2.

In spite of these efforts, reports of fetal exposure continued to accumulate through the 1990s.10 As a result, in 2002 the Pregnancy Prevention Program was modified to include additional measures (see Box 3) and was renamed SMART (System to Manage Accutane Related Teratogenicity).11The SMART program has not been adopted in Canada.

Figure
  • Download figure
  • Open in new tab
  • Download powerpoint

Box 3.

At the outset, the FDA indicated that, if SMART did not succeed in reducing gestational exposures to isotretinoin, additional restrictions would be imposed on the drug. In February 2004, an FDA advisory committee recommended that, in view of continuing safety issues, a mandatory registration for isotretinoin users and prescribers should be implemented.12

The expiry of the patent exclusivity of Accutane has opened up a lucrative market, prompting the rapid introduction of 3 generic forms of the drug in the United States: Amnesteen (November 2002), Sotret (December 2002) and Claravis (April 2003). Over 30 generic forms of isotretinoin are now available internationally. Currently, several manufacturers are considering the introduction of generic isotretinoin in Canada.

As part of the Motherisk program, we have been monitoring isotretinoin use since 1991. Between January 2002 and December 2003, we received 11 calls from women who had become pregnant while taking Accutane. Of these, only 4 had recalcitrant nodular acne, the only indication approved by Health Canada. A similar trend continues in the United States, where only 2 of 11 cases collected in 2003 by the Organization of Teratology Information Services had the labelled indication.

Moreover, although the drug was originally intended to be prescribed by dermatologists, many family physicians now prescribe it. Of the 11 Canadian women who consulted Motherisk, only 5 had a prescription written by a dermatologist, only 5 had seen printed information on the Pregnancy Prevention Program, and only 2 had signed a consent form. Only 1 of the 11 reported using 2 forms of contraception, yet 10 of the women had been warned verbally about fetal risk. Of the 5 prescriptions written by dermatologists, only 3 were for recalcitrant nodular acne.

The introduction of generic forms of isotretinoin, together with decreasing prices, will further increase the use of this drug by sexually active young women. It is also evident that the means used to avert the tremendous teratogenic risk of isotretinoin have not been effective. If, 20 years after the drug's introduction in clinical use, cases of fetal exposure continue to be reported, we see little reason to believe that the SMART program will be sufficient to reverse this trend. The flooding of the market with new and cheaper forms of generic isotretinoin is likely to endanger the lives of many more unborn Canadian babies. We need to take steps to protect the unborn from irresponsible prescribing; simply warning women (and their partners) about fetal risk is not enough.

We propose that certification and registration be required for physicians who wish to prescribe isotretinoin. Certification would entail a brief training program that covers the dos and don'ts of prescribing, followed by successful completion of a test. Training can be offered as CME in accredited institutions or through the Internet. Successful Web-based programs of this kind do exist. For example, US researchers who wish to be involved in publicly funded research involving humans must pass the NIH-initiated test on bioethics.13

A registration program works very well with respect to methadone prescribing in many countries, including Canada, the United Kingdom, Israel, France and Australia.14 The administration of such a program for isotretinoin could be handled provincially by pharmacists' organization, colleges of physicians or other suitable organizations. As part of this new strategy, Internet sales of the drug should be prohibited. In parallel, it would make sense to involve more meaningfully the pharmacists who dispense isotretinoin, who should present to female patients verbal and printed instructions that reinforce the information given by physicians.

One may argue that certification for isotretinoin prescription is not justified, as many other medications can have severe adverse effects. However, irresponsible prescribing of isotretinoin damages innocent fetuses who did not consent to exposure. The proposed program is easy to implement and can help to prevent irreparable, life-long damage to unborn children. We urge Health Canada, the manufacturers, physicians, pharmacists and their associations to adopt this initiative.

Footnotes

  • This article has been peer reviewed.

    Contributors: Gideon Koren initiated, coordinated and wrote the commentary. Marina Avner conducted the study in the Motherisk program and reviewed the literature. Neil Shear was responsible for the dermatology aspects of this commentary.

    Acknowledgement: Dr. Koren is a Senior Scientist with the Canadian Institute for Health Research. His work is supported in part by Jonathan's Allert, The Hospital for Sick Children, Toronto, Ont.

    Competing interests: Neil Shear has received educational grants from Hoffman- La Roche.

    Correspondence to: Dr. Gideon Koren, Division of Clinical Pharmacology, The Hospital for Sick Children, 555 University Ave., Toronto ON M5G 1X8; fax 416 813-7562, gkorensickkids.ca

References

  1. 1.↵
    Adverse effects with isotretinoin. FDA Drug Bull 1983;13:21-2.
    OpenUrlPubMed
  2. 2.↵
    Shear NH. Oral isotretinoin: prescribers beware. CMAJ 1999;160(12):1723-4.
    OpenUrlFREE Full Text
  3. 3.↵
    Wysowski DK, Swann J, Vega A. Use of isotretinoin (Accutane) in the United States: rapid increase from 1992 through 2000. J Am Acad Dermatol 2002;46: 505-9.
    OpenUrlCrossRefPubMed
  4. 4.↵
    Cunliffe WJ, van de Kerkhof PC, Caputo R, Cavicchini S, Cooper A, Fyrand OL, et al. Roaccutane treatment guidelines: results of an international survey. Dermatology 1997;194(4):351-7.
    OpenUrlPubMed
  5. 5.↵
    Ortonne JP. Oral isotretinoin treatment policy. Do we all agree? Dermatology 1997;195(Suppl 1):34-7.
  6. 6.↵
    Wieder R, Pavlick AC, Bryan M, Hameed M, Baredes S, Pliner L, et al. Phase I/II trial of accutane as a potentiator of carboplatin and paclitaxel in squamous cell carcinoma. Am J Clin Oncol 2002;25(2):447-50.
    OpenUrlPubMed
  7. 7.↵
    Reynolds CP, Lemons RS. Retinoid therapy of childhood cancer. Hematol Oncol Clin North Am 2002;15:867-910.
    OpenUrl
  8. 8.↵
    Lammer EJ, Chen DT, Hoar RM, Agnish ND, Benke PJ, Braun JT, et al. Retinoic acid embryopathy. N Engl J Med 1985;313(14):837-41.
    OpenUrlPubMed
  9. 9.↵
    Roche Canada. Information for the consumer. Available: www.rochecanada.com/pdf/Accutane%20PI%20E.pdf (accessed 2004 Apr 21).
  10. 10.↵
    Pastuszak AP, Koren G. The retinoid pregnancy prevention program. Koren G, editor. In: Retinoids in clinical practice: the risk-benefit ratio. New York: Marcel Dekker; 1993. p. 147-76.
  11. 11.↵
    Lowenstein EJ. Isotretinoin made S.M.A.R.T. and simple. Cutis 2002;70:115-20.
    OpenUrlPubMed
  12. 12.↵
    Elliott VS. FDA panel back patient registry for acne drug. AMNews 2004 Mar 22/29. Available: www.ama-assn.org/amednews/2004/03/22/hlsc0322.htm#w1 (accessed 2004 Apr 17).
  13. 13.↵
    National Institutes of Health. Human participant protections education for research teams. Bethesda (MD): The Institutes; 2002. Available: http://69.5.4.33/c01/ (accessed 2004 Apr 17).
  14. 14.↵
    Bell J, Dru A, Fischer B, Levit S, Sarfraz MA. Substitution therapy for heroin addiction. Subst Use Misuse 2002;37:1149-78.
    OpenUrlPubMed
PreviousNext
Back to top

In this issue

Canadian Medical Association Journal: 170 (10)
CMAJ
Vol. 170, Issue 10
11 May 2004
  • Table of Contents
  • Index by author

Article tools

Respond to this article
Print
Download PDF
Article Alerts
To sign up for email alerts or to access your current email alerts, enter your email address below:
Email Article

Thank you for your interest in spreading the word on CMAJ.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Generic isotretinoin: a new risk for unborn children
(Your Name) has sent you a message from CMAJ
(Your Name) thought you would like to see the CMAJ web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Generic isotretinoin: a new risk for unborn children
Gideon Koren, Marina Avner, Neil Shear
CMAJ May 2004, 170 (10) 1567-1568; DOI: 10.1503/cmaj.1040317

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
‍ Request Permissions
Share
Generic isotretinoin: a new risk for unborn children
Gideon Koren, Marina Avner, Neil Shear
CMAJ May 2004, 170 (10) 1567-1568; DOI: 10.1503/cmaj.1040317
Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like

Jump to section

  • Article
    • Footnotes
    • References
  • Figures & Tables
  • Responses
  • Metrics
  • PDF

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Cited By...

  • Patient-physician-regulator triad
  • Patient-physician-regulator triad
  • Google Scholar

More in this TOC Section

  • How can Canada’s health systems improve care for people with chronic obstructive pulmonary disease?
  • Minimally invasive procedures in gender-affirming care: the case for public funding across Canada
  • Time for Canada to align with global innovations in treatment for tuberculosis
Show more Commentary

Similar Articles

Collections

  • Topics
    • Dermatology
    • Drugs: adverse reactions
    • Maternal-fetal medicine
    • Pharmacology & toxicology

 

View Latest Classified Ads

Content

  • Current issue
  • Past issues
  • Collections
  • Sections
  • Blog
  • Podcasts
  • Alerts
  • RSS
  • Early releases

Information for

  • Advertisers
  • Authors
  • Reviewers
  • CMA Members
  • CPD credits
  • Media
  • Reprint requests
  • Subscribers

About

  • General Information
  • Journal staff
  • Editorial Board
  • Advisory Panels
  • Governance Council
  • Journal Oversight
  • Careers
  • Contact
  • Copyright and Permissions
CMAJ Group

Copyright 2023, CMA Impact Inc. or its licensors. All rights reserved. ISSN 1488-2329 (e) 0820-3946 (p)

All editorial matter in CMAJ represents the opinions of the authors and not necessarily those of the Canadian Medical Association or its subsidiaries.

To receive any of these resources in an accessible format, please contact us at CMAJ Group, 500-1410 Blair Towers Place, Ottawa ON, K1J 9B9; p: 1-888-855-2555; e: [email protected]

CMA Civility, Accessibility, Privacy

 

Powered by HighWire